3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
2
Sezary Syndrome
2
Recurrence
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancers
1
Interventions
Cyclophosphamide
17
fludarabine
16
fludarabine phosphate
11
venetoclax
9
Azacitidine
9
Rituximab
8
Nivolumab
7
Melphalan
7
Tacrolimus
6
Cytarabine
6
Specimen Handling
5
Sirolimus
5
Ipilimumab
5
Clofarabine
5
CTLA-4 Antigen
5
Antilymphocyte Serum
5
belinostat
4
aldesleukin
4
Thiotepa
4
Standard of Care
4
Practice Guidelines as Topic
4
Mycophenolic Acid
4
Methotrexate
4
Magnetic Resonance Spectroscopy
4
Interleukin-2
4
Granulocyte Colony-Stimulating Factor
4
Dexamethasone
4
Busulfan
4
Bortezomib
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Neoplasms
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT07036133
2026-02-11
SPI-FOL-102
Acrotech Biopharma Inc.
Phase 1
Recruiting
24 enrolled